<DOC>
	<DOCNO>NCT00349518</DOCNO>
	<brief_summary>The purpose study assess safety dasatinib imatinib intolerant resistant patient chronic phase chronic myeloid leukemia , advanced phase chronic myeloid leukemia Philadelphia chromosome positive acute lymphoblastic leukemia . The efficacy drug kind patient also document .</brief_summary>
	<brief_title>Study Dasatinib Imatinib Resistant Intolerant Subjects With Chronic Advanced Phase CML Philadelphia Chromosome Positive ALL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Males female , 18 old CP AD CML Ph+ ALL Intolerant resistant imatinib ECOG PS 02 ( CP CML ) ECOG PS 03 ( AD CML Ph+ ALL ) Adequate hepatic renal function Pregnant breastfeeding female History significant cardiac disease History significant bleeding disorder ( CML )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Chronic Advanced Phase CML</keyword>
	<keyword>Philadelphia Chromosome Positive ALL imatinib intolerance resistance</keyword>
</DOC>